Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12834220 | 0.97 | KMT2A (0.46) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL12833881 | 0.90 | KMT2A (0.45) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL12834435 | 0.89 | TBK1 (0.47) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL12834008 | 0.88 | TBK1 (0.42) | ALDH1A1KDM4EMAPTMAPK1TBK1 | |
| SCHEMBL14090419 | 0.88 | RIPK1 (0.46) | ALDH1A1KDM4EMAPTMAPK1TBK1 | |
| SCHEMBL12833813 | 0.87 | DRD4 (0.52) | TBK1SMN1; SMN2AKT1 | |
| SCHEMBL14090689 | 0.87 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL12833996 | 0.86 | SLC6A7 (0.48) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL12833886 | 0.86 | LOXL2 (0.39) | ALDH1A1KDM4EMAPTMAPK1TBK1 | |
| SCHEMBL12833471 | 0.85 | FLT3 (0.41) | ALDH1A1KDM4EMAPTMAPK1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | MEN1 1879/4885KMT2A 1726/4885ALDH1A1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.